Market Cap
$1.6B
FBRX
Forte Biosciences, Inc.
—
Market cap$1.6B
ConsensusHold
12-mo target$73.00 (-5.2%)
▲ Bullish
Analyst conviction 6/10
High Impact Filing (7/10)20 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on FBRX right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Buy (55%)
Inst. Holders
50 funds
Inst. Value
$278.2M
Inst. Activity
20 buys / 11 sells
SEC Reports
12
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 2, 2026 SEC Sep 2, 2026 SEC
Two shelf registration statements (File Nos. 333-286226 and 333-256611) for Forte Biosciences became effective on Septem
EFFECT — Impact 6/10
Forte Biosciences had four shelf registration statements (File Nos. 333-296425, 333-283814, 333-274257, 333-224880) decl
EFFECT — Impact 7/10
Aug 28, 2026 listing_status
Aug 27, 2026 SEC Delisted: FBRX — removed from the Nasdaq symbol directory
Forte Biosciences, Inc. - Common Stock
Nasdaq filed a Form 25-NSE with the SEC on August 27, 2026, to remove Forte Biosciences (FBRX) common stock from listing
25-NSE — Impact 9/10
Aug 27, 2026 Insider
GRYSKA DAVID W disposed of 2,000 shares
Director
Aug 27, 2026 Insider
GRYSKA DAVID W disposed of 18,353 shares
Director
Aug 27, 2026 Insider
VINCENT RICHARD G disposed of 18,353 shares
Director
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
1,222,862 shares ($26.0M)
Analyst ratings buy % -40.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
55% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jul 28, 2026 | Barclays | DOWNGRADE | Equal-Weight | 54% |
| Jul 21, 2026 | Barclays | INITIATE | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| Aug 1, 2026 | 2 | 4 | 5 | 0 | 0 | 55% | |
| Jul 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% |
Price targets
Where 4 covering analysts think FBRX trades over the next 12 months.
$73.00 -5.2% upside Sell
Current$76.99 Low$61.00 Median$77.00 High$77.00 4 analysts
$61.00$77.00
Analyst rating Buy· 2.5/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 1 bullish, 8 bearish, 1 mixed, 2 neutral · avg impact 6.2/10.
BEARISHEFFECT6/10
Two shelf registration statements (File Nos. 333-286226 and 333-256611) for Forte Biosciences became
Sep 2, 2026
BEARISHEFFECT7/10
Forte Biosciences had four shelf registration statements (File Nos. 333-296425, 333-283814, 333-2742
Sep 2, 2026
BEARISH25-NSE9/10
Nasdaq filed a Form 25-NSE with the SEC on August 27, 2026, to remove Forte Biosciences (FBRX) commo
Aug 27, 2026
BULLISH8-K8/10
Forte Biosciences (FBRX) has entered into a definitive merger agreement to be acquired by argenx (AR
Jul 27, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 28, 2026
listing_status
Delisted: FBRX — removed from the Nasdaq symbol directory
Forte Biosciences, Inc. - Common Stock
Aug 28, 2026
trading_halt
Halt Resumed: FBRX — trading resumed after D (Security Deletion)
Halted 2026-08-26T23:50:00.000Z | Resumed 2026-08-28T04:00:01.000Z
Aug 27, 2026
ftd
FTD: FBRX — 18,920 shares ($1.5M) failed to deliver
Settlement: 20260827, Price: $76.99, FTD Value: $1,456,650.8, FORTE BIOSCIENCES INC
Aug 26, 2026
trading_halt
Trading Halt: FBRX — D (Security Deletion)
Forte Biosciences Inc Cmn Stk | Market: NASDAQ | Code: D — Security Deletion
Aug 26, 2026
trading_halt
Trading Halt: FBRX — T12 (Additional Information Requested)
Forte Biosciences Inc Cmn Stk | Market: NASDAQ | Code: T12 — Additional Information Requested
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.09 | $-1.09–$-1.09 | -10.1% | -16.9% | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-1.11 | $-1.11–$-1.11 | 23.4% | -13.4% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-4.48 | $-4.48–$-4.48 | 4.9% | -16.8% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $-4.08 | $-5.91–$-2.89 | 9.0% | -0.9% | 0↑ 1↓ | $0.0B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.090 | — |
| 7d ago | $-0.935 | -0.155 |
| 30d ago | $-0.932 | -0.158 |
| 60d ago | $-1.005 | -0.085 |
| 90d ago | $-1.005 | -0.085 |
Institutional ownership
Which big funds own FBRX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $278.2M total value (13,091,052 shares) as of 2026-Q2. Top holders: FEDERATED, FRED, Jupiter. Net buying activity: 20 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FEDERATED HERMES, INC. | 2,110,516 | $44.8M | 16.1% | — |
| FRED ALGER MANAGEMENT, LLC | 1,439,697 | $30.6M | 11.0% | — |
| Jupiter Topco LLC | 1,373,060 | $29.2M | 10.5% | — |
| BlackRock, Inc. | 1,222,862 | $26.0M | 9.3% | DOUBLED +1755.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 861,737 | $18.3M | 6.6% | ADD +62.1% |
| Woodline Partners LP | 712,753 | $15.1M | 5.4% | DOUBLED +114.7% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 700,000 | $14.9M | 5.3% | TRIM -26.3% |
| MILLENNIUM MANAGEMENT LLC | 655,199 | $13.9M | 5.0% | ADD +93.9% |
| CITADEL ADVISORS LLC | 547,415 | $11.6M | 4.2% | DOUBLED +134.6% |
| FMR LLC | 502,826 | $10.7M | 3.8% | ADD +47.6% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 65,921 | 1,222,862 | +1755.0% | $26.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 531,692 | 861,737 | +62.1% | $18.3M |
| Woodline Partners LP | DOUBLED | 331,987 | 712,753 | +114.7% | $15.1M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 950,000 | 700,000 | -26.3% | $14.9M |
| MILLENNIUM MANAGEMENT LLC | ADD | 337,983 | 655,199 | +93.9% | $13.9M |
| CITADEL ADVISORS LLC | DOUBLED | 233,369 | 547,415 | +134.6% | $11.6M |
| FMR LLC | ADD | 340,695 | 502,826 | +47.6% | $10.7M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 125,442 | 473,280 | +277.3% | $10.1M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 111,788 | 418,891 | +274.7% | $8.9M |
| STATE STREET CORP | DOUBLED | 54,821 | 328,522 | +499.3% | $7.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | GRYSKA DAVID W | Director | D | 2,000 | — | — |
| Aug 27, 2026 | GRYSKA DAVID W | Director | D | 18,353 | — | — |
| Aug 27, 2026 | VINCENT RICHARD G | Director | D | 18,353 | — | — |
| Aug 27, 2026 | GRYSKA DAVID W | Director | U | 5,940 | — | — |
| Aug 27, 2026 | FINCK BARBARA K | Director | D | 1,000 | — | — |
| Aug 27, 2026 | GRYSKA DAVID W | Director | D | 2,000 | — | — |
| Aug 27, 2026 | Riley Antony A | CHIEF FINANCIAL OFFICER | D | 750 | — | — |
| Aug 27, 2026 | FINCK BARBARA K | Director | D | 166 | — | — |
| Aug 27, 2026 | VINCENT RICHARD G | Director | D | 31,000 | — | — |
| Aug 27, 2026 | GRYSKA DAVID W | Director | D | 1,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for FBRX.
Shares short
1,632,328
Settlement Aug 14, 2026
Change vs prior
-14.3%
Semi-monthly cycle
Days to cover
1.5
At avg daily volume
Of shares outstanding
≈7.7%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Aug 26, 2026 | T12 | Info Requested | Not resumed |
| Aug 26, 2026 | D | Deletion | Resumed |
| Jul 9, 2026 | LUDP | Volatility Pause | Resumed |
All FBRX filing & press-release reports (12)
- EFFECT reportSep 2, 2026
- EFFECT reportSep 2, 2026
- 25-NSE reportAug 27, 2026
- 8-K reportJul 27, 2026
- EFFECT reportJun 11, 2026
- S-3/A reportJun 8, 2026
- S-3 reportJun 5, 2026
- 8-K reportJun 2, 2026
- 8-K reportMay 14, 2026
- 8-K reportApr 21, 2026
- 8-K reportApr 9, 2026
- 424B5 reportApr 8, 2026